PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19933924-7 2010 Treatment of wild-type mice with pioglitazone attenuated cardiac hypertrophy and fibrosis, extracellular signal-regulated kinase phosphorylation, and transforming growth factor-beta1 expression in response to Ang II. Pioglitazone 33-45 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 209-215 19933924-8 2010 Pioglitazone also increased the plasma adiponectin level and phosphorylation of cardiac AMP-activated protein kinase in wild-type mice in the presence of Ang II. Pioglitazone 0-12 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 154-160 19933924-9 2010 The suppressive effects of pioglitazone on Ang II-induced cardiac hypertrophy and fibrosis were diminished in adiponectin-deficient mice. Pioglitazone 27-39 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 43-49 19933924-11 2010 These data provide direct evidence that pioglitazone protects against Ang II-induced pathological cardiac remodeling via an adiponectin-dependent mechanism. Pioglitazone 40-52 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 70-76 18931513-10 2009 Administration of pioglitazone to AngII-infused ApoE(-/-) mice significantly reduced aortic concentrations of OPG and metalloproteinase 9. Pioglitazone 18-30 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 34-39 18511847-6 2008 Pioglitazone attenuated AngII-induced fibrosis, macrophage accumulation, and osteopontin expression in both wild-type and cPPARgamma(-/-) mice but induced hypertrophy in a PPARgamma-dependent manner. Pioglitazone 0-12 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 24-29 16714359-0 2006 Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Pioglitazone 122-134 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-14 16714359-3 2006 We examined the potential antifibrotic effect of the combination of a statin (pravastatin) and a PPAR-gamma ligand (pioglitazone) in ANG II-treated mouse cardiac fibroblasts. Pioglitazone 116-128 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 133-139 16714359-4 2006 ANG II treatment induced procollagen-1 expression, which was inhibited by pravastatin and pioglitazone in a dose-dependent fashion. Pioglitazone 90-102 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 0-6 16714359-5 2006 Pretreatment of fibroblasts with low therapeutic concentrations of either pravastatin (0.1 microM) or pioglitazone (5 microM) only slightly decreased ANG II-induced NADPH oxidase expression, superoxide anion production, and procollagen-1 expression; however, the combination of pravastatin and pioglitazone markedly modulated these effects of ANG II. Pioglitazone 102-114 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 150-156 16714359-5 2006 Pretreatment of fibroblasts with low therapeutic concentrations of either pravastatin (0.1 microM) or pioglitazone (5 microM) only slightly decreased ANG II-induced NADPH oxidase expression, superoxide anion production, and procollagen-1 expression; however, the combination of pravastatin and pioglitazone markedly modulated these effects of ANG II. Pioglitazone 102-114 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 343-349 16714359-10 2006 Thus it appears that there is a positive interaction between pravastatin and pioglitazone in modulating ANG II-mediated oxidative stress, inhibiting MAPK activation, and procollagen-1 expression. Pioglitazone 77-89 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 104-110 11889020-4 2002 METHODS AND RESULTS: Treatment of cultured cardiac myocytes with PPARgamma ligands such as troglitazone, pioglitazone, and rosiglitazone inhibited Ang II-induced upregulation of skeletal alpha-actin and atrial natriuretic peptide genes and an increase in cell surface area. Pioglitazone 105-117 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 147-153 24100253-5 2013 The effects of pioglitazone on AngII-induced connective tissue growth factor (CTGF) expression and cell proliferation were assessed in primary-cultured mouse atrial fibroblasts. Pioglitazone 15-27 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 31-36 24100253-6 2013 The influences of pioglitazone on AngII-induced L-type calcium channel (ICa-L) alpha1c expression and current density were evaluated in atrial myocytes (HL-1). Pioglitazone 18-30 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 34-39 24100253-7 2013 Pioglitazone attenuated AngII-induced CTGF expression and proliferation in atrial fibroblasts, and pioglitazone also inhibited the expression or phosphorylation of AngII-induced transforming growth factor-beta1 (TGF-beta1), tumor necrosis factor receptor associated factor 6 (TRAF6), TGF-beta-associated kinase 1 (TAK1) and Smad2/3. Pioglitazone 0-12 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 24-29 24100253-7 2013 Pioglitazone attenuated AngII-induced CTGF expression and proliferation in atrial fibroblasts, and pioglitazone also inhibited the expression or phosphorylation of AngII-induced transforming growth factor-beta1 (TGF-beta1), tumor necrosis factor receptor associated factor 6 (TRAF6), TGF-beta-associated kinase 1 (TAK1) and Smad2/3. Pioglitazone 99-111 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 164-169 24100253-8 2013 In HL-1 cells, pioglitazone suppressed AngII-induced ICa-L alpha1c expression and current density as well as CAMP responsive element binding protein (CREB) phosphorylation. Pioglitazone 15-27 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 39-44 24100253-9 2013 Besides, pioglitazone inhibited AngII-induced production of AngII type I receptor (AT1R) and downregulation of PPAR-gamma in both atrial fibroblasts and HL-1 cells. Pioglitazone 9-21 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 32-37 24100253-9 2013 Besides, pioglitazone inhibited AngII-induced production of AngII type I receptor (AT1R) and downregulation of PPAR-gamma in both atrial fibroblasts and HL-1 cells. Pioglitazone 9-21 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 60-65 24100253-10 2013 In conclusion, Pioglitazone suppresses AngII-induced CTGF expression and proliferation in atrial fibroblasts, which might be at least in part related with its inhibitory effects on TGF-beta1/Smad2/3 and TGF-beta1/TRAF6/TAK1 signaling pathways. Pioglitazone 15-27 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 39-44 24100253-11 2013 Moreover, pioglitazone also attenuates AngII-induced ICa-L remodeling in HL-1 cells, which might be at least in part associated with its inhibitory effect on CREB phosphorylation. Pioglitazone 10-22 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 39-44 25152439-0 2015 Pioglitazone inhibits angiotensin II-induced atrial fibroblasts proliferation via NF-kappaB/TGF-beta1/TRIF/TRAF6 pathway. Pioglitazone 0-12 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 22-36 25152439-1 2015 The exact mechanisms underlying inhibitory effects of pioglitazone (Pio) on Angiotensin II (AngII)-induced atrial fibrosis are complex and remain largely unknown. Pioglitazone 54-66 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 76-90 25152439-1 2015 The exact mechanisms underlying inhibitory effects of pioglitazone (Pio) on Angiotensin II (AngII)-induced atrial fibrosis are complex and remain largely unknown. Pioglitazone 54-66 angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Mus musculus 92-97